English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Effective methods of treating UC patients is one of the most important problems. The inclusion of biological drugs in clinical practice leads to an improvement in the treatment of moderate and severe UC, but from 10 to 20% of patients lose their response within a year, which leads to the need to optimize the dose or switch to another drug. The use of janus kinase inhibitors – a new class of targeted synthetic drugs for the treatment of active ulcerative colitis – allows for a rapid clinical response when switching from TNF-α inhibitors. Pronounced clinical efficacy is usually observed 2-8 weeks after the start of treatment. A clinical case of a patient with ulcerative colitis who did not respond to treatment with anti-TNF is presented. Modern approaches to the diagnosis of ulcerative colitis and treatment tactics are reflected, as well as therapeutic possibilities for overcoming the secondary inefficiency of TNF inhibitors by using janus kinase inhibitors

Management of Patients with Ulcerative Colitis Who Did Not Respond to Anti-TNF Treatment